

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

ADOPTION OF THE NEW ARTICLES

Sino Biopharmaceutical Limited (the “**Company**”) proposes to amend its existing amended and restated articles of association (the “**Existing Articles**”) to, among others, (i) comply with the Core Shareholder Protection Standards as set out in Appendix 3 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited; (ii) keep up with technological developments and to provide flexibility to the Company in relation to the conduct of general meetings including allowing general meetings to be held as a hybrid meeting or an electronic meeting; and (iii) incorporate housekeeping amendments (collectively, the “**Proposed Amendments**”).

In view of the Proposed Amendments, the Board proposes to adopt the amended and restated articles of association (the “**New Articles**”), which shall consolidate all the Proposed Amendments, in substitution for and to the exclusion of the Existing Articles.

The Proposed Amendments and the adoption of the New Articles are subject to the approval of the shareholders of the Company by way of a special resolution to be proposed at the forthcoming annual general meeting of the Company.

Details of the Proposed Amendments and the New Articles will be set out in the circular to be despatched to the shareholders of the Company in due course together with a notice of the annual general meeting.

By Order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 25 April 2022

As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.